Durable Oncologic Outcomes Reported for RARP

Share this content:

ATLANTA—Robotic-assisted radical prostatectomy (RARP) is associated with long-term biochemical relapse-free survival, according to a study presented at the American Urological Association 2012 annual meeting.

Bertram Yuh, MD, and fellow investigators at the City of Hope National Medical Center in Duarte, Calif., studied 401 patients underwent RARP. Median follow-up was 71 months. The researchers defined biochemical recurrence as a serum PSA greater than 0.2 ng/ml following prostatectomy. The overall complication rate was 14%, with a positive margin rate of 24%. The five-year biochemical relapse-free survival for the cohort was 85%.

The investigators concluded that their contemporary series demonstrated durable oncologic control and safety.

The patients had a median age of 64 years and a median body mass index of 28 kg/m2. The cohort was 89% Caucasian. The median operative time was 2.7 hours and median estimated blood loss was 200 mL.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters